Your browser doesn't support javascript.
loading
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.
Hilf, Norbert; Kuttruff-Coqui, Sabrina; Frenzel, Katrin; Bukur, Valesca; Stevanovic, Stefan; Gouttefangeas, Cecile; Platten, Michael; Tabatabai, Ghazaleh; Dutoit, Valerie; van der Burg, Sjoerd H; Straten, Per Thor; Martinez-Ricarte, Francisco; Ponsati, Berta; Okada, Hideho; Lassen, Ulrik; Admon, Arie; Ottensmeier, Christian H; Ulges, Alexander; Kreiter, Sebastian; von Deimling, Andreas; Skardelly, Marco; Migliorini, Denis; Kroep, Judith R; Idorn, Manja; Rodon, Jordi; Piro, Jordi; Poulsen, Hans S; Shraibman, Bracha; McCann, Katy; Mendrzyk, Regina; Lower, Martin; Stieglbauer, Monika; Britten, Cedrik M; Capper, David; Welters, Marij J P; Sahuquillo, Juan; Kiesel, Katharina; Derhovanessian, Evelyna; Rusch, Elisa; Bunse, Lukas; Song, Colette; Heesch, Sandra; Wagner, Claudia; Kemmer-Bruck, Alexandra; Ludwig, Jorg; Castle, John C; Schoor, Oliver; Tadmor, Arbel D; Green, Edward; Fritsche, Jens.
  • Hilf N; Immatics Biotechnologies GmbH, Tübingen, Germany.
  • Kuttruff-Coqui S; Immatics Biotechnologies GmbH, Tübingen, Germany.
  • Frenzel K; BioNTech AG, Mainz, Germany.
  • Bukur V; BioNTech AG, Mainz, Germany.
  • Stevanovic S; Eberhard Karls Universität Tübingen, Tübingen, Germany.
  • Gouttefangeas C; German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany.
  • Platten M; Eberhard Karls Universität Tübingen, Tübingen, Germany.
  • Tabatabai G; German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany.
  • Dutoit V; CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
  • van der Burg SH; University Hospital Heidelberg, Heidelberg, Germany.
  • Straten PT; German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.
  • Martinez-Ricarte F; Medical Faculty Mannheim, Mannheim, Germany.
  • Ponsati B; Eberhard Karls Universität Tübingen, Tübingen, Germany.
  • Okada H; German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany.
  • Lassen U; University Hospital Tübingen, Tübingen, Germany.
  • Admon A; Geneva University Hospital, Geneva, Switzerland.
  • Ottensmeier CH; CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
  • Ulges A; Leiden University Medical Center, Leiden, The Netherlands.
  • Kreiter S; CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
  • von Deimling A; Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark.
  • Skardelly M; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
  • Migliorini D; Vall d'Hebron University Hospital, Barcelona, Spain.
  • Kroep JR; BCN Peptides SA, Barcelona, Spain.
  • Idorn M; University of California, San Francisco, San Francisco, CA, USA.
  • Rodon J; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Piro J; Ringhospitalet, Copenhagen, Denmark.
  • Poulsen HS; Technion - Israel Institute of Technology, Haifa, Israel.
  • Shraibman B; University of Southampton, Southampton, UK.
  • McCann K; Immatics Biotechnologies GmbH, Tübingen, Germany.
  • Mendrzyk R; BioNTech AG, Mainz, Germany.
  • Lower M; CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
  • Stieglbauer M; University Hospital Heidelberg, Heidelberg, Germany.
  • Britten CM; German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.
  • Capper D; University Hospital Tübingen, Tübingen, Germany.
  • Welters MJP; Geneva University Hospital, Geneva, Switzerland.
  • Sahuquillo J; Leiden University Medical Center, Leiden, The Netherlands.
  • Kiesel K; Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark.
  • Derhovanessian E; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
  • Rusch E; Vall d'Hebron University Hospital, Barcelona, Spain.
  • Bunse L; M. D. Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Song C; BCN Peptides SA, Barcelona, Spain.
  • Heesch S; Ringhospitalet, Copenhagen, Denmark.
  • Wagner C; Technion - Israel Institute of Technology, Haifa, Israel.
  • Kemmer-Bruck A; University of Southampton, Southampton, UK.
  • Ludwig J; Immatics Biotechnologies GmbH, Tübingen, Germany.
  • Castle JC; BioNTech AG, Mainz, Germany.
  • Schoor O; Eberhard Karls Universität Tübingen, Tübingen, Germany.
  • Tadmor AD; CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
  • Green E; BioNTech AG, Mainz, Germany.
  • Fritsche J; CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
Nature ; 566(7745): E13, 2019 02.
Article en En | MEDLINE | ID: mdl-30733620
ABSTRACT
The additional author support information was erroneously omitted from the Supplementary Information. This has been corrected online.
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Año: 2019 Tipo del documento: Article